What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings?

Zymeworks Inc. (NYSE:ZYME) – Analysts at HC Wainwright increased their Q2 2025 earnings estimates for shares of Zymeworks in a research report issued to clients and investors on Tuesday, May 20th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.47). HC Wainwright currently has a “Neutral” rating and a $13.00 target price on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Zymeworks’ Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.04) EPS.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. The company had revenue of $27.11 million during the quarter, compared to analyst estimates of $20.65 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm’s revenue was up 170.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.42) EPS.

Other equities research analysts have also recently issued reports about the company. TD Cowen assumed coverage on Zymeworks in a report on Tuesday. They issued a “buy” rating on the stock. TD Securities initiated coverage on Zymeworks in a research report on Tuesday. They issued a “buy” rating on the stock. Citigroup lifted their price target on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. Finally, Lifesci Capital initiated coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Zymeworks Stock Down 3.9%

ZYME stock opened at $11.48 on Thursday. Zymeworks has a 52 week low of $8.21 and a 52 week high of $17.70. The firm has a 50-day simple moving average of $11.78 and a 200-day simple moving average of $13.34. The stock has a market capitalization of $798.74 million, a P/E ratio of -7.65 and a beta of 1.24.

Hedge Funds Weigh In On Zymeworks

Institutional investors have recently bought and sold shares of the company. Barclays PLC grew its stake in shares of Zymeworks by 476.3% in the 3rd quarter. Barclays PLC now owns 154,384 shares of the company’s stock valued at $1,937,000 after buying an additional 127,595 shares during the period. SG Americas Securities LLC grew its position in Zymeworks by 30.4% in the fourth quarter. SG Americas Securities LLC now owns 26,782 shares of the company’s stock worth $392,000 after acquiring an additional 6,239 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Zymeworks by 6.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company’s stock worth $214,000 after acquiring an additional 940 shares during the last quarter. Empowered Funds LLC raised its position in Zymeworks by 5.1% in the fourth quarter. Empowered Funds LLC now owns 352,753 shares of the company’s stock valued at $5,164,000 after purchasing an additional 17,092 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Zymeworks by 18.1% in the 4th quarter. Rhumbline Advisers now owns 103,876 shares of the company’s stock valued at $1,521,000 after purchasing an additional 15,920 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Ecor1 Capital, Llc purchased 468,356 shares of the stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $12.48 per share, with a total value of $5,845,082.88. Following the transaction, the director now owns 16,802,141 shares in the company, valued at $209,690,719.68. The trade was a 2.87% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 1,405,768 shares of company stock worth $16,773,032 over the last ninety days. Corporate insiders own 1.92% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.